Physician profile
Heather Lamb
NPI 1457774846
$13,471.90
in general payments reported to CMS, 2019-2025
60 companies · $3,882 in 2025
The $3,882 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,663 · 2022: $2,626 · 2023: $3,053 · 2024: $2,248 · 2025: $3,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,636 · Travel and Lodging: $2,133 · Education: $394 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,635.96 |
| Travel and Lodging | $2,132.80 |
| Education | $393.99 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $3,590.95 | 2025 | |
| Janssen Biotech, INC. | $862.86 | 2021-2025 | Rybrevant, Erleada, Akeega |
| Merck Sharp & Dohme LLC | $659.51 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $559.85 | 2021-2024 | |
| Seagen INC. | $544.75 | 2021-2023 | Tivdak, Tukysa, Adcetris |
| Celgene Corporation | $519.15 | 2022-2024 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $514.89 | 2021-2024 | Xtandi, Padcev, Xospata |
| Genzyme Corporation | $491.28 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $406.27 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $332.28 | 2021-2023 | Imbruvica |
| Eisai INC. | $319.01 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $308.45 | 2021-2024 | Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $300.75 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $290.73 | 2021-2024 | Enhertu, Imfinzi, Calquence |
| Amgen INC. | $263.29 | 2021-2023 | Lumakras, Xgeva, Nplate |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $238.93 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.89 | 2022-2024 | Fruzaqla, Alunbrig, Iclusig |
| Incyte Corporation | $193.22 | 2021-2024 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $191.79 | 2021-2024 | Libtayo |
| Daiichi Sankyo INC. | $184.07 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Lilly USA, LLC | $183.09 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $169.09 | 2021-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $139.03 | 2021-2024 | Xpovio |
| Pharmaessentia USA Corporation | $135.13 | 2024-2025 | Besremi |
| Array Biopharma INC | $120.17 | 2022-2024 | Lorbrena, Braftovi, Mektovi |
| Gilead Sciences, INC. | $108.39 | 2022-2024 | |
| Sobi, INC | $99.71 | 2022-2024 | |
| Genentech USA, INC. | $93.47 | 2023 | Tecentriq, Alecensa, Lunsumio |
| Tersera Therapeutics LLC | $93.41 | 2022-2024 | Zoladex, Xermelo |
| Sumitomo Pharma America, INC. | $88.56 | 2023-2024 | Orgovyx |
| G1 Therapeutics, INC. | $86.66 | 2022-2023 | Cosela |
| Glaxosmithkline, LLC. | $78.61 | 2021-2024 | Zejula, Shingrix, Ojjaara |
| Mirati Therapeutics, INC. | $78.10 | 2023-2024 | Krazati |
| Abbvie INC. | $75.71 | 2023-2024 | |
| Myovant Sciences INC. | $71.94 | 2022 | |
| Emd Serono, INC. | $64.86 | 2023-2024 | Bavencio |
| Alexion Pharmaceuticals, INC. | $61.11 | 2021-2024 | Ultomiris |
| Kite Pharma, INC. | $61.00 | 2021-2022 | |
| Morphosys, US INC. | $60.38 | 2021-2024 | Monjuvi |
| Taiho Oncology, INC. | $56.41 | 2021-2024 | |
| Adc Therapeutics America, INC. | $55.53 | 2024 | |
| Cti Biopharma Corp. | $53.73 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $46.91 | 2022-2023 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.93 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $37.79 | 2022-2023 | Givlaari |
| Amag Pharmaceuticals, INC. | $33.19 | 2021-2022 | |
| Dova Pharmaceuticals | $28.73 | 2021 | |
| Genmab U.S., INC. | $24.67 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $21.36 | 2024 | Ayvakit |
| Adaptive Biotechnologies Corporation | $21.06 | 2023 | Clonoseq |
| Agios Pharmaceuticals, INC. | $20.66 | 2024 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $20.66 | 2022 | |
| Macrogenics, INC. | $20.55 | 2022 | |
| Ge Healthcare | $19.00 | 2022 | |
| Epizyme, INC. | $18.71 | 2021 | |
| Foundation Medicine, INC. | $18.42 | 2022 | |
| Smith+Nephew, INC. | $18.13 | 2022 | |
| Global Blood Therapeutics, INC. | $17.39 | 2022 | |
| Servier Pharmaceuticals LLC | $16.71 | 2023 | |
| Pharmacosmos Therapeutics INC. | $15.02 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.